In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

X-Ceptor Therapeutics Inc.

Division of Exelixis Inc.
www.xceptor.com

Latest From X-Ceptor Therapeutics Inc.

VC Term Sheets: Idiosyncratic VC Procedures and Customs

Certain idiosyncratic practices of the venture capital community may cause newcomers seeking funding to wonder whether they have somehow stumbled into a strange and irrational land. This final installment of the "VC Mindset" series looks at some of the more curious VC term-sheet practices.
Business Strategies

Exelixis/GSK: Using Project Financing to Accelerate R&D

Productivity in biotech is a better problem to have than its opposite-but paying the higher-than-expected development costs makes it still a problem. Thanks to a variety of new project financing sources, and a particularly clever approach to amending its alliance with GlaxoSmithKline, Exelixis is fact trying to turn research productivity into a source of non-dilutive capital.
BioPharmaceutical Business Strategies

Feeding the Machine: Exelixis Buys X-Ceptor

Exelixis' needs to address its increasing burn rate--expected to hit 90 million this year. With a stock mired around $8, any significant equity financing would be dilutive. Partnering was the obvious answer--except that Exelixis didn't have much to partner. By acquiring X-Ceptor Therapeutics it gets a set of much-needed near-term partnering opportunities, and it did so without significantly increasing its projected burn.
BioPharmaceutical Business Strategies

X-Ceptor Therapeutics Inc.

The field of nuclear receptor drug discovery boasts few industrial-strength programs. X-Ceptor Therapeutics Inc., a 1999 spin-out from Ligand Pharmaceuticals Inc., is one of the few dedicated players in this area of drug discovery.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Exelixis Inc.
  • Senior Management
  • Kevin Kinsella, Chmn. & CEO
    Sanford J Madigan, PhD, VP, Corp. Dev. & Strategic Planning
    Richard A Heyman, PhD, VP, R&D & CSO
  • Contact Info
  • X-Ceptor Therapeutics Inc.
    Phone: (858) 458-4500
    4757 Nexus Center Dr.
    Ste. 200
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register